Original Publication Date: 1 June, 2014
Publication / Source: Clinical Lipidology
Authors: Paulo JC Lin, Ying Kee Tam, Pieter R Cullis
Efficient delivery of siRNA to cancer cells after systemic administration poses a significant challenge. While many methods of nucleic acid delivery have been described, encapsulation of siRNA in lipid nanoparticles (LNPs) represents the most clinically advanced delivery approach. Currently, there are two siRNA-LNP-based treatments (ALN-VSP and TKM-PLK1) in clinical trials targeting solid tumors, with additional studies ongoing for noncancer diseases.